Des-gamma-carboxy prothrombin (DCP) is an abnormal form of prothrombin measured in blood as a tumor marker for hepatocellular carcinoma (HCC), the most common primary liver cancer. The same marker is also called PIVKA-II, meaning protein induced by vitamin K absence or antagonist-II. HCC cells can produce incompletely carboxylated prothrombin because their vitamin K-dependent processing is abnormal. However, cancer is not the only reason DCP rises. Vitamin K deficiency, warfarin or other vitamin K antagonists, severe cholestasis, malabsorption, and some liver conditions can also increase it. DCP is therefore not a stand-alone diagnostic test. It is interpreted with liver imaging, alpha-fetoprotein (AFP), liver disease history, and sometimes AFP-L3 or composite scores such as GALAD or GAAD. In a person with known HCC whose DCP was elevated before treatment, serial values can help monitor response or recurrence. A falling level may support successful treatment, while a sustained rise can prompt further imaging or evaluation.
- DCP and PIVKA-II refer to the same general abnormal prothrombin biomarker, although laboratory assays may report different units and cutoffs.
- There is no universal normal range: common decision limits include assay-specific values such as about 40 mAU/mL, but the laboratory’s own reference is the one to use.
- High DCP can occur with HCC, but vitamin K deficiency, warfarin therapy, cholestasis, and malabsorption can cause false-positive elevations.
- DCP is often combined with AFP and AFP-L3 rather than used alone for HCC risk assessment or biomarker models.
- Serial DCP is most useful for monitoring when the marker was clearly elevated before HCC treatment and confounding vitamin K factors are stable.
Table of Contents
- What DCP/PIVKA-II Measures
- DCP Normal Range and What High Levels Mean
- How DCP Is Used for HCC Risk and Diagnosis
- Vitamin K, Medications, and Other False-Positive Causes
- DCP in HCC Surveillance and Imaging Decisions
- DCP for HCC Treatment Monitoring and Recurrence
- DCP With AFP, AFP-L3, GALAD, and GAAD
- Testing, Limitations, and What to Do With a High Result
What DCP/PIVKA-II Measures
Normal prothrombin is a vitamin K-dependent clotting protein made by the liver. Before it can function properly, several glutamic-acid residues must undergo gamma-carboxylation, a vitamin K-dependent processing step. When that step is incomplete, abnormal prothrombin molecules enter the bloodstream.
DCP is short for des-gamma-carboxy prothrombin. The alternate name PIVKA-II refers to the same phenomenon: protein induced by vitamin K absence or antagonist-II. The two names are often used interchangeably in HCC literature, although specific commercial assays can differ in calibration, antibodies, and units.
HCC cells may produce DCP because malignant hepatocytes have disrupted vitamin K uptake, recycling, or carboxylation machinery. Tumor-related DCP production is biologically distinct from ordinary clotting tests. A person can therefore have an elevated DCP without a dramatic change in prothrombin time, and vice versa.
DCP is one of several serum biomarkers used in liver-cancer risk assessment. Alpha-fetoprotein is the best-known HCC blood marker, while AFP-L3 measures a specific AFP fraction. Because tumors do not all produce the same marker, combining biologically different markers can detect patterns that one test alone may miss.
DCP should not be confused with a general liver-function test. It does not directly measure bilirubin, albumin, liver enzymes, or the liver’s overall synthetic function. It is an abnormal prothrombin species with both tumor-marker and vitamin K-related interpretations.
DCP Normal Range and What High Levels Mean
There is no universal DCP reference range. Some assays report milli-arbitrary units per milliliter (mAU/mL), while others report ng/mL or other units. A commonly used cutoff in some HCC studies and clinical platforms is around 40 mAU/mL, but thresholds vary by assay, population, and purpose.
The raw number should never be compared with a cutoff from a different method. A result reported in mAU/mL is not directly interchangeable with a result in ng/mL.
| Pattern | Possible meaning | What matters next |
|---|---|---|
| Within assay reference range | Does not exclude HCC | Continue appropriate imaging surveillance or diagnostic evaluation |
| Mild elevation | May reflect vitamin K-related factors or HCC | Review medications, nutrition, cholestasis, and imaging |
| Marked elevation | Raises concern for HCC in the right clinical setting | Assess imaging and exclude vitamin K antagonism or deficiency |
| Falling after HCC treatment | May support a reduction in viable tumor burden | Compare with post-treatment imaging |
| Persistent or rising after treatment | May indicate residual disease, progression, or recurrence | Review confounders and consider repeat imaging |
Higher DCP values often correlate with larger tumor burden, vascular invasion, or more aggressive HCC biology in population studies. Yet no DCP level can assign an HCC stage or prove vascular invasion in an individual. Those findings come from imaging and pathology.
A normal DCP also does not rule out small or early HCC. Some early tumors produce little DCP, and biomarker sensitivity is incomplete. This is why liver-cancer surveillance and diagnosis remain imaging-centered.
How DCP Is Used for HCC Risk and Diagnosis
DCP is most relevant in people already at increased risk for HCC, such as those with cirrhosis or selected chronic hepatitis B populations. In that setting, the marker can supplement—but does not replace—recommended surveillance and diagnostic imaging.
Current major guidance emphasizes ultrasound with AFP for routine HCC surveillance in appropriate at-risk adults. Biomarkers such as DCP and AFP-L3 are promising and are included in risk algorithms, but they are not universally recommended as stand-alone surveillance tests.
When surveillance imaging reveals a suspicious liver lesion, diagnosis may sometimes be made by characteristic multiphasic CT or MRI features in a patient with cirrhosis or another qualifying risk state. DCP can add supportive information, especially when AFP is normal, but an elevated marker does not substitute for the imaging criteria or biopsy when tissue confirmation is needed.
The marker’s value partly comes from its biological independence from AFP. Some HCCs produce AFP but little DCP; others produce DCP with normal AFP. A broader liver cancer biomarker panel can therefore provide complementary risk information.
DCP is not suitable for screening people at low risk simply because they want a “liver cancer blood test.” False positives from vitamin K-related conditions and false negatives from marker-negative tumors would lead to misleading reassurance or unnecessary workup.
Vitamin K, Medications, and Other False-Positive Causes
The biology of DCP makes vitamin K status central to interpretation. If the liver cannot perform normal vitamin K-dependent carboxylation, abnormal prothrombin can accumulate even without cancer.
Important non-cancer causes include:
- Warfarin and other vitamin K antagonists. These medications intentionally block vitamin K recycling and can substantially raise PIVKA-II/DCP.
- Vitamin K deficiency. Poor intake alone is uncommon as a major cause in healthy adults, but deficiency can occur with severe illness, malnutrition, prolonged inadequate intake, or fat-malabsorption disorders.
- Cholestasis or biliary obstruction. Bile is needed for absorption of fat-soluble vitamins, including vitamin K, so obstructive jaundice can increase DCP.
- Malabsorption. Pancreatic, intestinal, or biliary disease can reduce vitamin K absorption.
- Prolonged broad-spectrum antibiotic exposure. Altered gut flora and poor nutritional status can contribute to deficiency in susceptible patients.
- Advanced liver disease. Complex changes in synthesis, nutrition, and cholestasis can affect abnormal prothrombin levels.
These factors are not minor details. A patient on warfarin can have a DCP result that is uninterpretable for HCC risk unless the assay and clinical context have a validated strategy for that situation.
The related PIVKA-II test is the same biomarker concept, so switching names does not remove the vitamin K problem. When a result is unexpected, the medication list, coagulation history, bilirubin, nutritional status, and evidence of cholestasis should be reviewed before attributing the elevation to cancer.
Giving vitamin K simply to “prove” whether an elevation is cancer-related is not a stand-alone diagnostic strategy. The response can be influenced by the underlying cause, timing, assay, and tumor biology. Imaging remains decisive.
DCP in HCC Surveillance and Imaging Decisions
HCC surveillance is different from testing a general population for cancer. Surveillance targets people whose underlying liver disease gives them a high enough annual HCC risk that repeated testing is worthwhile. In many guidelines, that includes most people with cirrhosis and selected people with chronic hepatitis B even without cirrhosis.
The standard surveillance interval is commonly every six months, because that timing balances tumor growth, detection opportunity, cost, and the practical burden of testing. Ultrasound is widely used, often together with AFP. DCP is being studied as an additional biomarker because ultrasound quality can be limited by obesity, nodular cirrhosis, or other technical factors and because AFP alone misses some tumors.
A key point is that an abnormal biomarker is usually a trigger for diagnostic evaluation, not a diagnosis. When a high-risk patient develops a suspicious imaging finding or a concerning biomarker pattern, the next step may be multiphasic CT or contrast-enhanced MRI. These studies look for arterial enhancement, washout, capsule appearance, growth, and other features used in standardized liver-imaging systems.
DCP can be especially informative when AFP is normal. For example, a patient with cirrhosis may have repeatedly normal AFP but a new, persistent DCP rise. That pattern may increase concern and justify careful imaging review, particularly if the patient is not taking a vitamin K antagonist and has no clear deficiency. The reverse can also happen: AFP may rise while DCP remains normal.
Biomarker discordance is therefore not a laboratory error by default. HCC is biologically heterogeneous, and tumors can express different secretory phenotypes. A marker-negative tumor is still real cancer if imaging or pathology establishes the diagnosis. Likewise, a marker-positive patient without a lesion should not be labeled as having HCC solely because of the blood test.
When ultrasound visualization is repeatedly poor, clinicians may use alternative imaging-based surveillance strategies in selected patients. The exact approach depends on liver-disease severity, renal function, contrast safety, local expertise, and guideline recommendations. DCP can support those decisions but does not replace the imaging modality chosen for surveillance or diagnosis.
DCP for HCC Treatment Monitoring and Recurrence
DCP can be useful after HCC diagnosis if it was elevated before treatment. Successful resection, ablation, embolization, radiation, transplantation, or systemic therapy may be followed by a decline as viable DCP-producing tumor decreases.
The most useful pattern is a consistent marker change that agrees with imaging. For example, a patient with a pretreatment DCP many times the upper limit may show a large decline after curative ablation and no residual enhancement on MRI. That combination is more convincing than either piece of information alone.
Persistent elevation after treatment raises several possibilities:
- Residual viable HCC
- Untreated tumor elsewhere in the liver
- Early recurrence
- Ongoing vitamin K deficiency or antagonism
- Cholestasis or another non-cancer source
- Assay-to-assay differences if laboratories changed
A rising DCP during surveillance after treatment can precede obvious progression in some patients, but it should trigger confirmation rather than an automatic treatment decision. Repeat biomarker testing, contrast-enhanced imaging, and review of vitamin K-related confounders are typical next steps.
DCP can also contribute prognostic information. Higher pretreatment levels have been associated with vascular invasion and recurrence risk in many cohorts. Transplant programs and research models have studied DCP as a marker of tumor biology beyond size and number, but specific transplant criteria vary by country and center.
DCP With AFP, AFP-L3, GALAD, and GAAD
No single HCC biomarker has ideal sensitivity and specificity, so combinations have attracted major interest.
AFP is widely used and inexpensive but can rise from active hepatitis or liver regeneration, and some HCCs produce little AFP. AFP-L3 is a glycoform of AFP associated more strongly with malignant hepatocytes. DCP captures a separate abnormal prothrombin pathway.
The GALAD score combines gender/sex, age, AFP, AFP-L3, and DCP. The GAAD score uses gender/sex, age, AFP, and DCP without AFP-L3. Large prospective studies have evaluated whether these combinations improve early HCC detection compared with individual markers.
Recent phase 3 validation has shown that GALAD can improve sensitivity in some settings but may also increase false-positive results. Comparative studies of GALAD and GAAD continue to refine which combination performs best and whether the extra marker meaningfully improves early detection.
These algorithms are important research and emerging clinical tools, but they do not mean an elevated DCP automatically produces a cancer diagnosis. A risk score estimates probability and identifies who may need closer evaluation; it still relies on imaging to establish HCC.
A practical advantage of combining markers is biological diversity. If an HCC is AFP-negative but DCP-positive, the DCP component may preserve signal. If it is DCP-negative but AFP-positive, the reverse can occur. The combination reduces dependence on one tumor phenotype.
Testing, Limitations, and What to Do With a High Result
DCP testing uses a standard blood sample. Fasting requirements vary by laboratory and are usually less important than medication and vitamin K context. Tell the clinician or laboratory if you take warfarin or another vitamin K antagonist, have jaundice, have a malabsorption disorder, or recently had major changes in nutrition or antibiotics.
Serial results are best measured with the same assay. Different platforms may report different units and use different decision limits, so an apparent change after switching laboratories can be misleading.
If you are at risk for HCC and DCP is high, the result should be interpreted alongside your surveillance history and liver imaging. A clinician may repeat the marker, check AFP and liver tests, review medication and vitamin K factors, and obtain contrast-enhanced CT or MRI if clinically appropriate.
If you already have HCC, a rising value deserves discussion with the liver or oncology team, particularly when it was a reliable marker at diagnosis. Do not change treatment based on the DCP number alone.
Seek prompt medical assessment for new jaundice, vomiting blood, black stools, confusion, rapidly increasing abdominal swelling, severe right-upper-abdominal pain, fainting, or other signs of decompensated liver disease or bleeding. These problems require clinical care regardless of the tumor-marker result.
The key question is not simply whether DCP is above a cutoff. It is whether the elevation reflects HCC biology, impaired vitamin K-dependent carboxylation, or both. That distinction requires the medication list, liver context, serial trend, and imaging.
For patients with chronic liver disease, it is also important not to let one reassuring biomarker delay scheduled surveillance. HCC can arise with normal AFP, normal DCP, or both. The surveillance plan is determined by underlying cancer risk, not by whether the latest tumor-marker panel happens to be negative. Keeping regular six-month appointments is often more important than repeatedly adding unvalidated blood markers between visits, unless the liver team has a specific reason to do so.
References
- The Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer 2025
- Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies 2025
- A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis 2024
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma 2023 (Guideline)
- Combination of serum alpha-fetoprotein, PIVKA-Ⅱ and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis 2024 (Meta-Analysis)
- The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States 2022
Disclaimer
This article is for general education and does not diagnose hepatocellular carcinoma or interpret an individual DCP/PIVKA-II result. Vitamin K status, warfarin therapy, cholestasis, liver disease, and assay method can substantially affect the marker. Discuss abnormal or changing DCP with a liver specialist or other qualified clinician and follow recommended imaging surveillance.
